The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
122572194 12257219 4 F 20160308 20160714 20160412 20160722 EXP CA-JNJFOC-20160406450 JANSSEN 15.08 YR T F Y 51.90000 KG 20160722 OT CA CA

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
122572194 12257219 1 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) N GAM08011 0 300 MG LYOPHILIZED POWDER
122572194 12257219 2 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) N GAM08011 0 300 MG LYOPHILIZED POWDER
122572194 12257219 3 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) N GAM08011 0 300 MG LYOPHILIZED POWDER
122572194 12257219 4 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) N GAM08011 0 300 MG LYOPHILIZED POWDER
122572194 12257219 5 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) N GAM08011 0 300 MG LYOPHILIZED POWDER
122572194 12257219 6 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) N GAM08011 0 300 MG LYOPHILIZED POWDER
122572194 12257219 7 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) N GAM08011 0 300 MG LYOPHILIZED POWDER
122572194 12257219 8 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) N GAM08011 0 300 MG LYOPHILIZED POWDER
122572194 12257219 9 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) N GAM08011 0 300 MG LYOPHILIZED POWDER
122572194 12257219 10 PS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) N GAM08011 103772 300 MG LYOPHILIZED POWDER
122572194 12257219 11 C IMURAN AZATHIOPRINE 1 Oral 0 100 G UNSPECIFIED QD

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
122572194 12257219 1 Crohn's disease
122572194 12257219 2 Crohn's disease
122572194 12257219 3 Crohn's disease
122572194 12257219 4 Crohn's disease
122572194 12257219 5 Crohn's disease
122572194 12257219 6 Colitis ulcerative
122572194 12257219 7 Colitis ulcerative
122572194 12257219 8 Colitis ulcerative
122572194 12257219 9 Colitis ulcerative
122572194 12257219 10 Colitis ulcerative

Outcome of event

Event ID CASEID OUTC COD
122572194 12257219 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
122572194 12257219 Diarrhoea
122572194 12257219 General physical health deterioration
122572194 12257219 Haematochezia
122572194 12257219 Inappropriate schedule of drug administration
122572194 12257219 Off label use
122572194 12257219 Product use issue

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
122572194 12257219 1 20160714 0
122572194 12257219 2 20160504 0
122572194 12257219 3 20160406 0
122572194 12257219 4 20160308 0
122572194 12257219 5 20160126 0
122572194 12257219 6 20160714 0
122572194 12257219 7 20160406 0
122572194 12257219 8 20160308 0
122572194 12257219 9 20160126 0
122572194 12257219 10 20160504 0